{"id":2214,"date":"2018-12-13T12:50:47","date_gmt":"2018-12-13T10:50:47","guid":{"rendered":"http:\/\/lupusgalicia.org\/?p=2214"},"modified":"2018-12-13T22:01:58","modified_gmt":"2018-12-13T20:01:58","slug":"en-curso-la-fase-1-de-la-terapia-potencial-de-lupus-ly3361237","status":"publish","type":"post","link":"https:\/\/lupusgalicia.org\/?p=2214","title":{"rendered":"En curso la fase 1 de la terapia potencial de lupus LY3361237"},"content":{"rendered":"<p><a href=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-2215 size-medium\" src=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155-300x200.jpg\" alt=\"\" width=\"300\" height=\"200\" srcset=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155-300x200.jpg 300w, https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155.jpg 500w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>El Instituto de Descubrimiento M\u00e9dico de Sanford Burnham Prebys&nbsp;&nbsp;(SBP) anunci\u00f3 que el ensayo cl\u00ednico de Fase 1 que eval\u00faa&nbsp;la seguridad de la<strong> terapia LY3361237<\/strong> de&nbsp;Eli Lilly&nbsp; <strong>le dio la primera dosis a su primer participante<\/strong>.<\/p>\n<p>El&nbsp;tratamiento&nbsp;se est\u00e1 desarrollando<strong> para enfermedades autoinmunes como el lupus,<\/strong> la psoriasis y la artritis reumatoide, donde el sistema inmunitario es hiperactivo y ataca las c\u00e9lulas y los tejidos sanos.&nbsp;Est\u00e1 dise\u00f1ado para inhibir la inflamaci\u00f3n dirigiendo y activando un receptor del punto de control inmunitario, y as\u00ed controlar las c\u00e9lulas inmunitarias.<\/p>\n<p>Se&nbsp;espera que el&nbsp;ensayo de la Fase 1 patrocinado por la farmac\u00e9utica Lilly, incluya a 85 adultos y determine la seguridad de LY3361237.&nbsp;A los participantes se les asignar\u00e1 aleatoriamente el tratamiento o un placebo, administrado ya sea debajo de la piel (por v\u00eda subcut\u00e1nea) o directamente en la sangre (por v\u00eda intravenosa).&nbsp; Los participantes permanecer\u00e1n en la unidad de investigaci\u00f3n cl\u00ednica durante cuatro d\u00edas despu\u00e9s del tratamiento.<\/p>\n<p>Adem\u00e1s de determinar la seguridad de LY3361237, que se llevar\u00e1 a cabo mediante la evaluaci\u00f3n de cualquier evento adverso asociado con el tratamiento, los investigadores tambi\u00e9n pretenden medir el perfil farmacocin\u00e9tico de la terapia, incluido cu\u00e1nto tarda en llegar al torrente sangu\u00edneo y cu\u00e1nto tarda el cuerpo en excretarlo.<\/p>\n<p>\u00ab<span style=\"color: #800080;\"><em>El hito de hoy es un importante paso adelante para los pacientes que padecen una enfermedad autoinmune<\/em>\u00ab<\/span>, dijo en un&nbsp;comunicado de prensa&nbsp;el Dr. Carl Ware, director del Centro de Enfermedades Infecciosas e Inflamatorias de SBP, con sede en La Jolla, California.<\/p>\n<p>\u00ab<span style=\"color: #800080;\"><em>Este avance tambi\u00e9n ilustra c\u00f3mo la comprensi\u00f3n fundamental de un proceso biol\u00f3gico, en este caso, el papel de los receptores de punto de control en la funci\u00f3n inmunol\u00f3gica, puede traducirse en el desarrollo de nuevos medicamentos<\/em><\/span>\u00ab, agreg\u00f3 el Dr. Ware.<\/p>\n<p><a href=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/Screen-Shot-2016-08-30-at-1.56.28-PM.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-2216\" src=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/Screen-Shot-2016-08-30-at-1.56.28-PM-300x300.jpg\" alt=\"\" width=\"300\" height=\"300\" srcset=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/Screen-Shot-2016-08-30-at-1.56.28-PM-300x300.jpg 300w, https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/Screen-Shot-2016-08-30-at-1.56.28-PM-150x150.jpg 150w, https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/Screen-Shot-2016-08-30-at-1.56.28-PM.jpg 363w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>LY3361237 es el resultado de la&nbsp;colaboraci\u00f3n establecida en 2015&nbsp;&nbsp;entre la compa\u00f1\u00eda Eli Lilly y Sanford-Burnham Medical Research Institute para desarrollar terapias novedosas contra el sistema inmunitario.&nbsp;Con esa asociaci\u00f3n se unieron la biotecnolog\u00eda y la experiencia de Lilly en inmunolog\u00eda con el conocimiento de Sanford-Burnham sobre las v\u00edas que regulan el sistema inmunol\u00f3gico, especialmente los puntos de control inmunitarios.<\/p>\n<p>\u00ab<span style=\"color: #800080;\"><em>Los trastornos inmunol\u00f3gicos, muchos de los cuales afectan de manera desproporcionada a las mujeres, afectan a millones de personas en todo el mundo y siguen siendo un \u00e1rea de gran necesidad m\u00e9dica no satisfecha<\/em>\u00ab<\/span>, dijo el Dr Ajay Nirula, vicepresidente de Inmunolog\u00eda en Lilly.<\/p>\n<p>&nbsp;<\/p>\n<pre>Noticia de<a href=\"https:\/\/lupusnewstoday.com\/2018\/11\/28\/phase-1-clinical-trial-testing-safety-of-potential-lupus-therapy-ly3361237-underway\/\"> LupusNewsToday <\/a>por la Dra Patricia Inacio 28.11.18<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>El Instituto de Descubrimiento M\u00e9dico de Sanford Burnham Prebys&nbsp;&nbsp;(SBP) anunci\u00f3 que el ensayo cl\u00ednico de Fase 1 que eval\u00faa&nbsp;la seguridad de la terapia LY3361237 de&nbsp;Eli Lilly&nbsp; le dio la primera dosis a su primer participante. El&nbsp;tratamiento&nbsp;se est\u00e1 desarrollando para enfermedades autoinmunes como el lupus, la psoriasis y la artritis reumatoide, donde el sistema inmunitario es [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2215,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[14,6,5,24],"tags":[52,42,38,46,16],"class_list":["post-2214","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-estudios","category-investigacion","category-lupus-internacional","category-mujer-lupica","tag-biomedica","tag-investigacion","tag-mujer-lupica","tag-nuevas-moleculas","tag-tratamientos"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\r\n<title>En curso la fase 1 de la terapia potencial de lupus LY3361237 - Asociaci\u00f3n Galega de Lupus<\/title>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/lupusgalicia.org\/?p=2214\" \/>\r\n<meta property=\"og:locale\" content=\"es_ES\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"En curso la fase 1 de la terapia potencial de lupus LY3361237 - Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"og:description\" content=\"El Instituto de Descubrimiento M\u00e9dico de Sanford Burnham Prebys&nbsp;&nbsp;(SBP) anunci\u00f3 que el ensayo cl\u00ednico de Fase 1 que eval\u00faa&nbsp;la seguridad de la terapia LY3361237 de&nbsp;Eli Lilly&nbsp; le dio la primera dosis a su primer participante. El&nbsp;tratamiento&nbsp;se est\u00e1 desarrollando para enfermedades autoinmunes como el lupus, la psoriasis y la artritis reumatoide, donde el sistema inmunitario es [&hellip;]\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/lupusgalicia.org\/?p=2214\" \/>\r\n<meta property=\"og:site_name\" content=\"Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LupusGalicia\/\" \/>\r\n<meta property=\"article:published_time\" content=\"2018-12-13T10:50:47+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2018-12-13T20:01:58+00:00\" \/>\r\n<meta property=\"og:image\" content=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155.jpg\" \/>\r\n\t<meta property=\"og:image:width\" content=\"500\" \/>\r\n\t<meta property=\"og:image:height\" content=\"334\" \/>\r\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\r\n<meta name=\"author\" content=\"Agal\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:creator\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:site\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Agal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2214#article\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2214\"},\"author\":{\"name\":\"Agal\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\"},\"headline\":\"En curso la fase 1 de la terapia potencial de lupus LY3361237\",\"datePublished\":\"2018-12-13T10:50:47+00:00\",\"dateModified\":\"2018-12-13T20:01:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2214\"},\"wordCount\":462,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2214#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155.jpg\",\"keywords\":[\"Biom\u00e9dica\",\"Investigaci\u00f3n\",\"mujer l\u00fapica\",\"Nuevas mol\u00e9culas\",\"Tratamientos\"],\"articleSection\":[\"Estudios\",\"Investigaci\u00f3n\",\"Lupus Internacional\",\"Mujer l\u00fapica\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=2214#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2214\",\"url\":\"https:\/\/lupusgalicia.org\/?p=2214\",\"name\":\"En curso la fase 1 de la terapia potencial de lupus LY3361237 - Asociaci\u00f3n Galega de Lupus\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2214#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2214#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155.jpg\",\"datePublished\":\"2018-12-13T10:50:47+00:00\",\"dateModified\":\"2018-12-13T20:01:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2214#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=2214\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2214#primaryimage\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155.jpg\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155.jpg\",\"width\":500,\"height\":334,\"caption\":\"Ensayo Cl\u00ednico\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2214#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/lupusgalicia.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"En curso la fase 1 de la terapia potencial de lupus LY3361237\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lupusgalicia.org\/#website\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"description\":\"Trabajando para y por las personas con Lupus\",\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lupusgalicia.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lupusgalicia.org\/#organization\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"width\":2560,\"height\":2522,\"caption\":\"Asociaci\u00f3n Galega de Lupus\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LupusGalicia\/\",\"https:\/\/x.com\/LupusGalicia\",\"https:\/\/www.instagram.com\/lupusgalicia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\",\"name\":\"Agal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"caption\":\"Agal\"},\"description\":\"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...\",\"sameAs\":[\"http:\/\/www.lupusgalicia.org\"],\"url\":\"https:\/\/lupusgalicia.org\/?author=1\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"En curso la fase 1 de la terapia potencial de lupus LY3361237 - Asociaci\u00f3n Galega de Lupus","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lupusgalicia.org\/?p=2214","og_locale":"es_ES","og_type":"article","og_title":"En curso la fase 1 de la terapia potencial de lupus LY3361237 - Asociaci\u00f3n Galega de Lupus","og_description":"El Instituto de Descubrimiento M\u00e9dico de Sanford Burnham Prebys&nbsp;&nbsp;(SBP) anunci\u00f3 que el ensayo cl\u00ednico de Fase 1 que eval\u00faa&nbsp;la seguridad de la terapia LY3361237 de&nbsp;Eli Lilly&nbsp; le dio la primera dosis a su primer participante. El&nbsp;tratamiento&nbsp;se est\u00e1 desarrollando para enfermedades autoinmunes como el lupus, la psoriasis y la artritis reumatoide, donde el sistema inmunitario es [&hellip;]","og_url":"https:\/\/lupusgalicia.org\/?p=2214","og_site_name":"Asociaci\u00f3n Galega de Lupus","article_publisher":"https:\/\/www.facebook.com\/LupusGalicia\/","article_published_time":"2018-12-13T10:50:47+00:00","article_modified_time":"2018-12-13T20:01:58+00:00","og_image":[{"width":500,"height":334,"url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155.jpg","type":"image\/jpeg"}],"author":"Agal","twitter_card":"summary_large_image","twitter_creator":"@LupusGalicia","twitter_site":"@LupusGalicia","twitter_misc":{"Escrito por":"Agal","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lupusgalicia.org\/?p=2214#article","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/?p=2214"},"author":{"name":"Agal","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665"},"headline":"En curso la fase 1 de la terapia potencial de lupus LY3361237","datePublished":"2018-12-13T10:50:47+00:00","dateModified":"2018-12-13T20:01:58+00:00","mainEntityOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=2214"},"wordCount":462,"commentCount":0,"publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=2214#primaryimage"},"thumbnailUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155.jpg","keywords":["Biom\u00e9dica","Investigaci\u00f3n","mujer l\u00fapica","Nuevas mol\u00e9culas","Tratamientos"],"articleSection":["Estudios","Investigaci\u00f3n","Lupus Internacional","Mujer l\u00fapica"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lupusgalicia.org\/?p=2214#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lupusgalicia.org\/?p=2214","url":"https:\/\/lupusgalicia.org\/?p=2214","name":"En curso la fase 1 de la terapia potencial de lupus LY3361237 - Asociaci\u00f3n Galega de Lupus","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=2214#primaryimage"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=2214#primaryimage"},"thumbnailUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155.jpg","datePublished":"2018-12-13T10:50:47+00:00","dateModified":"2018-12-13T20:01:58+00:00","breadcrumb":{"@id":"https:\/\/lupusgalicia.org\/?p=2214#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lupusgalicia.org\/?p=2214"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/?p=2214#primaryimage","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155.jpg","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2018\/12\/shutterstock_709073155.jpg","width":500,"height":334,"caption":"Ensayo Cl\u00ednico"},{"@type":"BreadcrumbList","@id":"https:\/\/lupusgalicia.org\/?p=2214#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/lupusgalicia.org\/"},{"@type":"ListItem","position":2,"name":"En curso la fase 1 de la terapia potencial de lupus LY3361237"}]},{"@type":"WebSite","@id":"https:\/\/lupusgalicia.org\/#website","url":"https:\/\/lupusgalicia.org\/","name":"Asociaci\u00f3n Galega de Lupus","description":"Trabajando para y por las personas con Lupus","publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lupusgalicia.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/lupusgalicia.org\/#organization","name":"Asociaci\u00f3n Galega de Lupus","url":"https:\/\/lupusgalicia.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","width":2560,"height":2522,"caption":"Asociaci\u00f3n Galega de Lupus"},"image":{"@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LupusGalicia\/","https:\/\/x.com\/LupusGalicia","https:\/\/www.instagram.com\/lupusgalicia\/"]},{"@type":"Person","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665","name":"Agal","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","caption":"Agal"},"description":"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...","sameAs":["http:\/\/www.lupusgalicia.org"],"url":"https:\/\/lupusgalicia.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2214"}],"version-history":[{"count":2,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2214\/revisions"}],"predecessor-version":[{"id":2236,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2214\/revisions\/2236"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/media\/2215"}],"wp:attachment":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}